SB successfully entered the clinical stage in 2011 with two clinical trials as the first non-viral vector being used to generate CD19-specific CAR-T cells for adjuvant immunotherapy targeting minimal residual disease of NHL and ALL after autologous (n = 7, ClinicalTrials.gov Identifier NCT00968760) or allogeneic (n = 19, ClinicalTrials.gov Identifier NCT01497184) hematopoietic stem cell transplantation (HSCT) [34]. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.